Clinical Trials Directory

Trials / Completed

CompletedNCT03827408

Nebulized Midazolam, Dexmedetomidine, and Their Combination in Sedation of Preschoolers Undergoing Dental Treatment

Nebulized Midazolam, Dexmedetomidine, and Their Combination in Sedation of Preschoolers Undergoing Dental Treatment: A Randomized Clinical Trial

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
72 (actual)
Sponsor
Nourhan M.Aly · Academic / Other
Sex
All
Age
4 Years – 6 Years
Healthy volunteers
Not accepted

Summary

The aim of the study is to evaluate the effect of nebulized Midazolam, Dexmedetomidine, and their combination as procedural, moderate sedative agents in preschoolers undergoing dental treatment.

Detailed description

Dental anxiety and fear related behaviors are global problems in Pediatric Dentistry. Preschoolers represent a dental behavior management problem and there is always a debate over the best behavioral management technique for preschoolers undergoing dental treatment. Moderate sedation is considered as an acceptable option. Children who need treatment under local anesthesia, for thirty minutes will be included in the study. A total of 72 uncooperative pediatric dental patients, of age range 4-6 years, will be selected from the Pediatric Dentistry and Dental Public Health Department, Faculty of Dentistry, Alexandria University, Egypt. The participants will be randomly allocated into 3 groups that will undergo a procedural sedation session via a nebulizer. Children of group I will receive nebulized solution of 0.5 mg/kg Midazolam, Group II will receive nebulized solution of 5µg/kg Dexmedetomidine, and Group III will receive a nebulized solution of 0.3 mg/kg Midazolam and 3µg/kg Dexmedetomidine respectively.

Conditions

Interventions

TypeNameDescription
DRUGMidazolam group (MDZ)IV Ampules of Dormicum 15mg/ 3ml, Hoffman-La Rouche Ltd., Basel, Switzerland
DRUGDexmedetomidine group (DEX)IV Ampules of Precedex 4mcg/ml, Hospira. Inc., Lake Forest,IL USA.
DRUGCombination of Midazolam and Dexmedetomidine (MDZ/DEX)Combination of Nebulized solution of 0.3 mg/kg Midazolam, and 3µg/kg Dexmedetomidine respectively.(

Timeline

Start date
2017-11-27
Primary completion
2019-08-29
Completion
2019-12-22
First posted
2019-02-01
Last updated
2020-01-22

Locations

1 site across 1 country: Egypt

Source: ClinicalTrials.gov record NCT03827408. Inclusion in this directory is not an endorsement.